Larimar Therapeutics, Inc.

Historical 13F Holders

Symbol
LRMR
CUSIP
517125100
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 517125100 since 12/18/2024, largest first.

Filer % of Class Filed
James E. Flynn 13D/A
34.4% 3/2/2026
Event 2/27/2026
Blue Owl Capital Holdings LP 13G/A 10.0% 5/14/2026
Event 3/31/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (6)
Opaleye Management Inc. 13G
4.8% 8/29/2025
Event 8/29/2025
BlackRock, Inc. 13G/A 4.8% 4/22/2025
Event 3/31/2025
Goldman Sachs Group Inc 13G/A
4.1% 5/13/2025
Event 3/31/2025
Millennium Management LLC 13G/A
3.5% 4/30/2026
Event 3/31/2026
Janus Henderson Group PLC 13G/A 0% 8/14/2025
Event 3/31/2025
RA Capital Management, L.P. 13G/A
0% 2/17/2026
Event 12/31/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 2 6.14 k $19.6 k
2026 Q2 171 95.5 M $293 M
2026 Q1 171 87.8 M $395 M
2025 Q4 140 72.7 M $277 M
2025 Q3 154 85.5 M $275 M
2025 Q2 127 62.4 M $180 M
2025 Q1 109 60.8 M $132 M
2024 Q4 125 63.4 M $245 M
2024 Q3 130 64.4 M $421 M
2024 Q2 116 65.4 M $474 M
2024 Q1 119 63.8 M $484 M
2023 Q4 78 39.7 M $181 M
2023 Q3 70 38.8 M $153 M
2023 Q2 68 39.0 M $120 M
2023 Q1 71 38.5 M $174 M
2022 Q4 51 38.8 M $160 M
2022 Q3 63 40.9 M $131 M
2022 Q2 42 14.4 M $28.2 M
2022 Q1 49 15.3 M $61.8 M
2021 Q4 51 14.7 M $158 M
2021 Q3 56 14.5 M $167 M
2021 Q2 47 14.5 M $143 M
2021 Q1 58 14.1 M $206 M
2020 Q4 44 14.3 M $305 M
2020 Q3 39 13.6 M $207 M
2020 Q2 38 13.0 M $166 M